A single administration resulted in dose-dependent tumor inhibition and prolonged survival without observable toxicity. These findings highlight [225Ac]Ac-Macropa-PEG4-FPA150 as a promising candidate for B7-H4 targeted TAT and support Macropa as an effective chelator for 225Ac radiopharmaceuticals.

TRIAL REGISTRATION NUMBER: NCT05067972. REGISTRATION DATE: 5 October, 2021.

P1/2, N=179, Terminated, Genmab | Active, not recruiting --> Terminated; The Sponsor has made a strategic decision to stop the development of GEN1047.

P1, N=96, Recruiting, ABL Bio, Inc. | Trial primary completion date: Jun 2025 --> Dec 2025

P1/2, N=65, Recruiting, ABL Bio, Inc.

P1/2, N=179, Active, not recruiting, Genmab | Trial completion date: Mar 2027 --> Dec 2025 | Trial primary completion date: Jan 2027 --> Dec 2025

Additionally, combining PF-07260437 with standard of care (palbociclib plus fulvestrant) and a checkpoint inhibitor (anti-PD-1) showed combinatorial benefits in an immune competent in vivo model. Finally, the manageable toxicity profile of PF-07260437 was highlighted in an exploratory toxicology study in cynomolgus monkeys. These data support the clinical testing of PF-07260437 for treating B7-H4 expressing solid tumors, including breast cancer.

P1, N=96, Recruiting, ABL Bio, Inc. | Trial primary completion date: Nov 2024 --> Jun 2025

P1, N=95, Terminated, Five Prime Therapeutics, Inc. | Phase classification: P1a/1b --> P1 | Completed --> Terminated; The Sponsor terminated the study for reasons unrelated to safety.

P1/2, N=179, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=400 --> 179

P1, N=110, Recruiting, Zhejiang Kanova Biopharmaceutical Co., LTD | Not yet recruiting --> Recruiting

P1, N=48, Completed, Cullinan Therapeutics Inc. | Recruiting --> Completed | N=108 --> 48 | Trial completion date: Jun 2024 --> Sep 2024